2008/06/04 by Julie R. Ingelfinger · 41 citations
Medicine · #Renin-Angiotensin System Studies #Hormonal Regulation and Hypertension #Blood Pressure and Hypertension Studies #Renin–angiotensin system #Aliskiren #Medicine #Angiotensin II #Vasoactive #Internal medicine #Angiotensin II receptor type 1 #Aldosterone #Endocrinology #Pharmacology #Receptor #Blood pressure
paper · doi:10.1056/nejme0803375
published in New England Journal of Medicine 358(23), 2503-2505 (Massachusetts Medical Society)
openalex publication_date 2008/06/04 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
The discovery 110 years ago that crude kidney extract elicited a pressor reaction provided the first evidence of the existence of the renin–angiotensin–aldosterone system, a major vasoactive system,1 and the complex actions and interactions of this important cascade are still unfolding. Over the past few decades, various components of the renin−angiotensin−aldosterone system have been elucidated more completely, and previously unknown members have been discovered.2 Drugs that specifically block various components of the renin−angiotensin−aldosterone system have been developed (Figure 1). Angiotensin-converting–enzyme (ACE) inhibitors block the conversion of angiotensin I to angiotensin II, and clinically available angiotensin-receptor blockers block the angiotensin II . . .